FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073181045> ?p ?o ?g. }

• W2073181045 endingPage "731" @default.
• W2073181045 startingPage "726" @default.
• W2073181045 abstract "In a randomized, controlled study we investigated the clinical efficacy of the microemulsion formulation of cyclosporine (Neoral) in comparison with Sandimmune (SIM) in the treatment of patients who underwent primary orthotopic liver transplantation (OLT).In total, 33 patients were randomized in a double-blind fashion before undergoing primary OLT to receive either Neoral or SIM. All 33 patients initially received intravenous cyclosporine, but as soon as it was tolerated, the oral study drug was initiated (median time, 3.6 days) and 17 patients received Neoral and 16 SIM (for both drugs, 10 mg/kg/day). Both groups were comparable with regard to age, sex, etiology of chronic liver disease, and hepatic biochemical profile. Episodes of rejection were diagnosed histologically and characterized as mild, moderate, or severe using criteria from the National Institute of Diabetes and Digestive and Kidney Diseases.Patients were followed for 1 year. Four patients in each group were discontinued prematurely. The reason for discontinuation of cyclosporine was drug-related complications in two of the NEO patients and in three of the SIM group; the other three were non-drug-related. Rejection episodes occurred in 9 of 17 patients (52.90%) in the Neoral group and in 9 of 16 patients (56.3%) in the SIM group. The total number of rejection episodes in each group was 14. However, in evaluating the severity of rejection histologically, nine episodes of rejection were characterized as moderate/ severe in the SIM group compared with only three in the Neoral group (P=0.027). Five of the nine moderate/severe rejection episodes in the SIM group occurred within the first 2 weeks after transplant. In contrast, moderate/severe rejection did not occur in the Neoral group in this early period. Two patients in the SIM group and no patients in the Neoral group required treatment with OKT3 for steroid-resistant rejection. There were no differences in mean doses or trough levels when comparing the two study groups. The incidence of adverse effects was similar in the two groups.Neoral is a safe and efficacious drug in the treatment of primary OLT patients. Given comparable doses of cyclosporine in each group over 1 year, there was no significant difference in the total number of rejection episodes between study groups. However, patients treated with Neoral had a lower incidence of moderate/severe histologic rejection and were free of steroid-resistant rejection when compared with SIM-treated patients." @default.
• W2073181045 created "2016-06-24" @default.
• W2073181045 creator A5026246814 @default.
• W2073181045 creator A5031764164 @default.
• W2073181045 creator A5042116952 @default.
• W2073181045 creator A5053268191 @default.
• W2073181045 creator A5061717823 @default.
• W2073181045 creator A5062859812 @default.
• W2073181045 creator A5090721170 @default.
• W2073181045 creator A5090787460 @default.
• W2073181045 date "1997-09-01" @default.
• W2073181045 modified "2023-10-12" @default.
• W2073181045 title "NEORAL COMPARED TO SANDIMMUNE IS ASSOCIATED WITH A DECREASE IN HISTOLOGIC SEVERITY OF REJECTION IN PATIENTS UNDERGOING PRIMARY LIVER TRANSPLANTATION1" @default.
• W2073181045 cites W1966769235 @default.
• W2073181045 cites W1967745415 @default.
• W2073181045 cites W1971111617 @default.
• W2073181045 cites W1981801952 @default.
• W2073181045 cites W2005677975 @default.
• W2073181045 cites W2055960142 @default.
• W2073181045 cites W2057388366 @default.
• W2073181045 cites W2078006847 @default.
• W2073181045 cites W2092075764 @default.
• W2073181045 cites W2150907300 @default.
• W2073181045 cites W2151141510 @default.
• W2073181045 cites W4205363739 @default.
• W2073181045 cites W4230154854 @default.
• W2073181045 cites W4249227909 @default.
• W2073181045 cites W4255940022 @default.
• W2073181045 doi "https://doi.org/10.1097/00007890-199709150-00011" @default.
• W2073181045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9311710" @default.
• W2073181045 hasPublicationYear "1997" @default.
• W2073181045 type Work @default.
• W2073181045 sameAs 2073181045 @default.
• W2073181045 citedByCount "38" @default.
• W2073181045 countsByYear W20731810452012 @default.
• W2073181045 countsByYear W20731810452016 @default.
• W2073181045 countsByYear W20731810452021 @default.
• W2073181045 crossrefType "journal-article" @default.
• W2073181045 hasAuthorship W2073181045A5026246814 @default.
• W2073181045 hasAuthorship W2073181045A5031764164 @default.
• W2073181045 hasAuthorship W2073181045A5042116952 @default.
• W2073181045 hasAuthorship W2073181045A5053268191 @default.
• W2073181045 hasAuthorship W2073181045A5061717823 @default.
• W2073181045 hasAuthorship W2073181045A5062859812 @default.
• W2073181045 hasAuthorship W2073181045A5090721170 @default.
• W2073181045 hasAuthorship W2073181045A5090787460 @default.
• W2073181045 hasBestOaLocation W20731810451 @default.
• W2073181045 hasConcept C126322002 @default.
• W2073181045 hasConcept C137627325 @default.
• W2073181045 hasConcept C141071460 @default.
• W2073181045 hasConcept C2776535732 @default.
• W2073181045 hasConcept C2778330430 @default.
• W2073181045 hasConcept C2778715236 @default.
• W2073181045 hasConcept C2779528694 @default.
• W2073181045 hasConcept C2779609443 @default.
• W2073181045 hasConcept C2911091166 @default.
• W2073181045 hasConcept C71924100 @default.
• W2073181045 hasConcept C90924648 @default.
• W2073181045 hasConceptScore W2073181045C126322002 @default.
• W2073181045 hasConceptScore W2073181045C137627325 @default.
• W2073181045 hasConceptScore W2073181045C141071460 @default.
• W2073181045 hasConceptScore W2073181045C2776535732 @default.
• W2073181045 hasConceptScore W2073181045C2778330430 @default.
• W2073181045 hasConceptScore W2073181045C2778715236 @default.
• W2073181045 hasConceptScore W2073181045C2779528694 @default.
• W2073181045 hasConceptScore W2073181045C2779609443 @default.
• W2073181045 hasConceptScore W2073181045C2911091166 @default.
• W2073181045 hasConceptScore W2073181045C71924100 @default.
• W2073181045 hasConceptScore W2073181045C90924648 @default.
• W2073181045 hasIssue "5" @default.
• W2073181045 hasLocation W20731810451 @default.
• W2073181045 hasLocation W20731810452 @default.
• W2073181045 hasLocation W20731810453 @default.
• W2073181045 hasOpenAccess W2073181045 @default.
• W2073181045 hasPrimaryLocation W20731810451 @default.
• W2073181045 hasRelatedWork W2026317945 @default.
• W2073181045 hasRelatedWork W2028553864 @default.
• W2073181045 hasRelatedWork W2041172286 @default.
• W2073181045 hasRelatedWork W2052606181 @default.
• W2073181045 hasRelatedWork W2070861676 @default.
• W2073181045 hasRelatedWork W2103964288 @default.
• W2073181045 hasRelatedWork W2104508578 @default.
• W2073181045 hasRelatedWork W2332689897 @default.
• W2073181045 hasRelatedWork W2469540238 @default.
• W2073181045 hasRelatedWork W2806166134 @default.
• W2073181045 hasVolume "64" @default.
• W2073181045 isParatext "false" @default.
• W2073181045 isRetracted "false" @default.
• W2073181045 magId "2073181045" @default.
• W2073181045 workType "article" @default.